HICKSVILLE, NY - September 16, 2025 (NEWMEDIAWIRE) - Nascent Pharma Holdings, Inc. (OTC Pink Limited: NASC) (the “Company”) announced today that the Financial Industry Regulatory Authority has completed the processing of the change of the Company’s name for trading purposes from Can B Corp. to Nascent Pharma Holdings, Inc. and the change of its trading symbol from “CANB” to “NASC.” These corporate actions become effective on September 16, 2025.
Effective today, the Company’s common stock will trade under the symbol “NASC” and the new CUSIP number for its common stock is 63108T105.
The name and symbol change follow the holding company reorganization completed in October 2024 pursuant to which Nascent Pharma Holdings, Inc. became the parent of Can B Corp.
About Nascent Pharma Holdings, Inc.: Nascent Pharma Holdings, Inc., a Florida corporation, is a forward-thinking pharmaceutical Intellectual Property (IP) company, focused on maximizing the value of its cannabis patent portfolios. It owns two issued patents registered with the US Patent and Trademark Office (USPTO) covering cannabis extracts and methods of preparation, emphasizing both composition and use.
Forward-Looking Statements
Forward-looking statements and risks and uncertainties discussed in this release contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, achievements, and the ultimate value of our patents could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of latest information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
Investors and Media:
info@nascentpharmaholding.com
(917) 658-7878
View the original release on www.newmediawire.com
